Seeking Alpha

Investors appear skeptical about the FDA's request for additional information from Sarepta...

Investors appear skeptical about the FDA's request for additional information from Sarepta Therapeutics (SRPT) regarding the company's Duchenne muscular dystrophy drug. CEO Chris Garabedian says he does not anticipate "an impact on SRPT's ongoing activities" from the FDA's request or from the delay it occasioned in the accelerated approval submission process. Nonetheless, the shares are -6.22% premarket. 
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|